drugset / Trial / NCT03698448
A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis
Phase 2/3
Withdrawn
AlgiPharma AS
Cystic Fibrosis Europe · collabCystic Fibrosis Foundation · collabEuropean Cystic Fibrosis Society · collabImperial College London · collabUniversity Hospital of Cologne · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Randomized, double blind, placebo controlled study. The study has two parts: Dose-finding part, followed by longer term follow-up (6 months)
Timeline
- Start
- 2021-09-01
- Primary completion
- 2022-10-01
- Completion
- 2022-11-01
Outcome
Outcome not reported
Stopped: “Determined not feasible”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | OligoG | Other / unclassified | 17.5 mg | Inhaled |
| Comparator | OligoG | Other / unclassified | 27.5 mg | Inhaled |
| Comparator | OligoG | Other / unclassified | 37.5 mg | Inhaled |